Menu
Search
|

Menu

Close
X

Audentes Therapeutics Inc BOLD.OQ (NASDAQ Stock Exchange Global Market)

40.85 USD
+1.78 (+4.56%)
As of 4:00 PM EDT
chart
Previous Close 39.07
Open 38.47
Volume 266,232
3m Avg Volume 123,911
Today’s High 41.46
Today’s Low 38.47
52 Week High 42.50
52 Week Low 15.74
Shares Outstanding (mil) 36.74
Market Capitalization (mil) 1,407.28
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.91 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.739
FY17
-2.743
FY16
-3.009
FY15
-1.259
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.14
Price to Sales (TTM)
vs sector
--
8.57
Price to Book (MRQ)
vs sector
4.07
4.34
Price to Cash Flow (TTM)
vs sector
--
22.77
Total Debt to Equity (MRQ)
vs sector
0.00
17.37
LT Debt to Equity (MRQ)
vs sector
0.00
12.92
Return on Investment (TTM)
vs sector
-33.25
13.17
Return on Equity (TTM)
vs sector
-34.35
15.14

EXECUTIVE LEADERSHIP

Natalie Holles
President, Chief Operating Officer, Since 2018
Salary: $360,500.00
Bonus: --
Matthew Patterson
Chief Executive Officer, Director, Since 2018
Salary: $441,760.00
Bonus: --
Thomas Schuetz
Co-Founder, Independent Director, Since 2013
Salary: --
Bonus: --
Thomas Soloway
Chief Financial Officer, Senior Vice President, Since 2017
Salary: $360,500.00
Bonus: --
David Nagler
Senior Vice President - Human Resources and Corporate Affairs, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

600 California St Fl 17
SAN FRANCISCO   CA   94108-2725

Phone: +1415.6386556

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

SPONSORED STORIES